Unravelling the role of denosumab in prostate cancer-Reference-Cited by-同舟云学术

Unravelling the role of denosumab in prostate cancer

Published:2011-03 Issue:9768 Volume:377 Page:785-786
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Aragon-Ching Jeanny B

Publisher

Elsevier BV

Subject

General Medicine

Reference10 articles.

1. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma;Carlin;Cancer,2000

2. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma;Saad;J Natl Cancer Inst,2002

3. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study;Fizazi;Lancet,2010

4. Osteoclast differentiation and activation;Boyle;Nature,2003

5. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer;Reed;J Urol,2004

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the vicious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis;Molecular Immunology;2019-06

2. Bone Disorders in Cancer;Osteoporosis Rehabilitation;2017

3. Cost–effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer;Expert Review of Pharmacoeconomics & Outcomes Research;2016-01-02

4. Advances in systemic therapies for metastatic castration-resistant prostate cancer;Future Oncology;2014-11

5. Management of Metastatic Bone Disease in the Elderly with Bisphosphonates and RANKL Inhibitors: Effectiveness and Safety;Bone Metastases;2013-10-11